Abstract:Abstract Abstract 3462 Acute myeloid leukemia (AML) bearing MLL (mixed lineage leukemia) translocations are associated with poor survival, and only fewer than 50% of the patients survive longer than 5 years. Thus, an improved strategy leading to a higher cure rate is urgently needed to treat MLL-associated AML. MicroRNAs (miRNAs), a class of small non-coding RNAs, have been postulated to be important gene expression regulators in all biology including human leukemia. Through large-scale, genome-wide miRNA expression profiling assays, we determined that miR-495 is significantly down-regulated in the majority of human AML samples, particularly, in those with MLL rearrangements. More interestingly, through correlating the expression signature of miR-495 with clinical outcome of AML patients, we revealed that a low expression level of miR-495 is a predictor of poor prognosis in most AML patients. Our further qPCR assays confirmed that the expression of miR-495 is even more significantly downregulated in MLL-rearranged AML primary patient samples and cell lines. Through in vitro colony-forming/replating assays and in vivo bone marrow transplantation studies, we found that forced expression of miR-495 significantly inhibits the capacity of the MLL-AF9 fusion gene to support colony formation in mouse bone marrow progenitor cells in vitro and to induce leukemia in vivo. In leukemia cell lines, overexpression of miR-495 greatly inhibits the viability of the cells, while increasing apoptosis. Furthermore, by using 3 algorithms for miR-495 3'UTR binding sites, we identified several well-known MLL leukemia-related genes, e. g. BMI1, MEF2C, BID and MEIS1, as potential targets of miR-495. Results of qPCR revealed that forced expression of miR-495 significantly inhibits the expression levels of these genes in leukemia cell lines, mouse bone marrow progenitor cells, as well as mouse peripheral blood cells with MLL fusion genes. Therefore we hypothesize that miR-495 may function as a tumor suppressor in AML with MLL rearrangements by targeting essential tumor-related genes. Further studies will focus on: 1) effects of miR-495 on the functions of target genes studied in vitro and in vivo; 2) the epigenetic mechanisms and the signaling pathways involved in regulating the expression level of miR-495 in human leukemia. Disclosures: No relevant conflicts of interest to declare.

Down-regulation of Lncrna NEAT1 Regulated by Mir-194-5p/dnmt3a Facilitates Acute Myeloid Leukemia.

Mir-22 Has a Potent Anti-Tumour Role with Therapeutic Potential in Acute Myeloid Leukaemia

MicroRNA-181a-mediated Downregulation of AC9 Protein Decreases Intracellular Camp Level and Inhibits ATRA-induced APL Cell Differentiation

miR-550-1 functions as a tumor suppressor in acute myeloid leukemia via the hippo signaling pathway

Long noncoding RNA NEAT1 modulates cell proliferation and apoptosis by regulating miR‐23a‐3p/SMC1A in acute myeloid leukemia

m(6)A Modification of lncRNA NEAT1 Regulates Chronic Myelocytic Leukemia Progression via miR-766-5p/CDKN1A Axis

LncRNA NEAT1 contributes to multiple myeloma progression via upregulating ARPC5 by sponging miR-133a

Inhibition of Long Non-Coding RNA NEAT1 Impairs Myeloid Differentiation in Acute Promyelocytic Leukemia Cells.

The Lncrna NEAT1 Inhibits Mirna-216B and Promotes Colorectal Cancer Progression by Indirectly Activating YY1

Epigenetic Landscape Analysis of Lncrnas in Acute Myeloid Leukemia with DNMT3A Mutations.

Lncrna NEAT1 Facilitates Melanoma Cell Proliferation, Migration, and Invasion Via Regulating Mir-495-3p and E2F3

The LncRNA NEAT1 Accelerates Lung Adenocarcinoma Deterioration and Binds to Mir-193a-3p as a Competitive Endogenous RNA.

The Tumor Suppressive Role of Mirna-370 by Targeting FoxM1 in Acute Myeloid Leukemia.

Long Non-Coding RNA LINC01018 Inhibits the Progression of Acute Myeloid Leukemia by Targeting Mir-499A-5p to Regulate PDCD4.

TET1-mediated microRNA-188-5p promoter hydroxymethylation regulates PTEN/PI3K/AKT signaling pathway in acute myeloid leukemia cells

Repression Of Mir-495, A Microrna Associated With Favorable Outcome Of Acute Myeloid Leukemia Patients, Is Required For The Mll-Associated Leukemogenesis

Study on the Immune Escape Mechanism of Acute Myeloid Leukemia With DNMT3A Mutation

LncRNA NEAT1/miR-204/NUAK1 Axis is a Potential Therapeutic Target for Non-Small Cell Lung Cancer

Investigating the Microrna-Mrna Regulatory Network in Acute Myeloid Leukemia

The Knockdown of MAGI2-AS3 Inhibits Drug Resistance in Acute Myeloid Leukemia by Up Regulating Mir-155

LncRNA SNHG1 Overexpression Regulates the Proliferation of Acute Myeloid Leukemia Cells Through Mir-488-5p/nup205 Axis